[C:1]([NH:5][C:6]([C:8]1[C:12]2=[N:13][C:14]([C:17]3[C:25]4[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH:27]([F:29])[F:28])[CH:24]=4)[N:19]([CH2:30][CH2:31][CH:32]([OH:34])[CH3:33])[N:18]=3)=[CH:15][N:16]=[C:11]2[N:10](C(C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[CH:9]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].FC(F)(F)C(O)=O>ClCCl>[C:1]([NH:5][C:6]([C:8]1[C:12]2=[N:13][C:14]([C:17]3[C:25]4[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH:27]([F:28])[F:29])[CH:24]=4)[N:19]([CH2:30][CH2:31][CH:32]([OH:34])[CH3:33])[N:18]=3)=[CH:15][N:16]=[C:11]2[NH:10][CH:9]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2]To a stirred solution of N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-hydroxybutyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide in dichloromethane (2 mL) was added drop-wise trifluoroacetic acid (1 mL) at room temperature. Then the reaction mixture was stirred for 1.5 hours. The solvent was removed under reduced pressure and the residue was purified by preparative-TLC (silica gel, petroleum ether:EtOAc=1:1) to give N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-hydroxybutyl)-1H-indazol-3-yl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (22 mg, 30% over three steps) as a white solid. MS: (M+H)+=473.2; 1H NMR (300 MHz, DMSO): δ 12.86 (s, 1H), 9.11 (s, 1H), 8.42 (s, 1H), 8.24 (d, 1H, J=1.8 Hz), 7.92-7.89 (m, 2H), 7.47-7.42 (m, 1H), 7.23 (t, 1H, J=74.4 Hz), 4.75-4.61 (m, 3H), 3.65 (brs, 1H), 2.06-1.92 (m, 2H), 1.53 (s, 9H), 1.15 (d, 3H, J=6.3 Hz).